SynthesisFrontiers in oncology2025
Prognostic significance of the pretreatment pan-immune-inflammation value in colorectal cancer patients: an updated meta-analysis.
Synthesis in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of the pretreatment pan-immune-inflammation value in patients with head and neck squamous cell carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Beyond the biopsy: the new era of non-invasive staging and biomarkers in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic importance of the pretreatment pan-immune-inflammation value (PIV) in colorectal cancer has been extensively documented, yet its role remains unclear. This study aims to conduct an updated meta-analysis to elucidate the relationship between the pretreatment PIV and long-term survival outcomes among patients diagnosed with colorectal cancer. Methods: A systematic literature review was performed in PubMed, Embase, Web of Science and CNKI to identify eligible studies from inception to January 18, 2025. The primary endpoints evaluated were survival outcomes. Hazard ratios (HRs) along with their corresponding 95% confidence intervals (CIs) for survival outcomes were extracted. A random-effects model was utilized to synthesize the findings. All statistical analyses were conducted using R software, version 4.2.1. Results: Out of 81 identified studies, a total of 14 retrospective studies including 6,192 colorectal cancer patients were ultimately included. In this meta-analysis, the pooled results demonstrated that patients with higher PIV exhibited significantly poorer overall survival (11 studies, HR=1.95; 95%CI:1.64-2.31; P<0.01; I Conclusion: Our study reveals that the pretreatment PIV can serve as a valuable biomarker for predicting long-term survival outcomes in patients with colorectal cancer, which may have important clinical implications for personalized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.